Clinical Trial Update: A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma [NA]

View source ↗

Summary

A single-center, single-arm Phase II study evaluating a combination of Iparomlimab and Tuvonralimab with Regorafenib for advanced second-line or higher hepatoce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Huai'an First People's Hospital | Conditions: Hepatocellular Carcinoma (HCC) | NA | Status: NOT_YET_RECRUITING